Old Web
English
Sign In
Acemap
>
authorDetail
>
S. Rivkin
S. Rivkin
Medical College of Wisconsin
Chemotherapy
Refractory
Pancreatic cancer
Rubitecan
Response rate (survey)
2
Papers
39
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase IA/IB Evaluation of Mammalian Cell-derived Glycosylated Recombinant Human Interleukin (SIGOSIX) before and after Cytotoxic Chemotherapy
2006
Annals of the New York Academy of Sciences
Paul S. Ritch
C. Keever
Joan H. Schiller
S. Rivkin
Patricia L. Witt
Sidney E. Grossberg
Robert L. Truitt
Howard A. Burris
D. D. Von Hoff
Louis Vaickus
D. Drechsler
Ernest C. Borden
Galazka Ar
James B. Breitmeyer
Abdul-Ahad Ak
Show All
Source
Cite
Save
Citations (1)
A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study
2004
Journal of Clinical Oncology
A. D. Jacobs
H. A. Burris
S. Rivkin
Paul S. Ritch
P. Eisenberg
K.L. Mettinger
Show All
Source
Cite
Save
Citations (38)
1